These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2935368)
1. Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus). Prahalada S; Carroad E; Hendrickx AG Contraception; 1985 Nov; 32(5):497-515. PubMed ID: 2935368 [TBL] [Abstract][Full Text] [Related]
2. Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis). Prahalada S; Carroad E; Cukierski M; Hendrickx AG Teratology; 1985 Dec; 32(3):421-32. PubMed ID: 2934853 [TBL] [Abstract][Full Text] [Related]
3. Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate. Carbone JP; Figurska K; Buck S; Brent RL Teratology; 1990 Aug; 42(2):121-30. PubMed ID: 2145652 [TBL] [Abstract][Full Text] [Related]
4. Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate + ethinylestradiol and progesterone + estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocephalus). Hendrickx AG; Korte R; Leuschner F; Neumann BW; Prahalada S; Poggel A; Binkerd PE; Günzel P Teratology; 1987 Feb; 35(1):119-27. PubMed ID: 3563930 [TBL] [Abstract][Full Text] [Related]
5. The effect of medroxyprogesterone acetate (Depo-Provera) on prenatal development in the baboon (Papio anubis): a preliminary study. Tarara R Teratology; 1984 Oct; 30(2):181-5. PubMed ID: 6238440 [TBL] [Abstract][Full Text] [Related]
6. Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. I. Eibs HG; Spielmann H; Hägele M Teratology; 1982 Feb; 25(1):27-36. PubMed ID: 6461082 [TBL] [Abstract][Full Text] [Related]
7. Teratogenic effects of Silastic intrauterine devices in the rat with or without added medroxyprogesterone acetate. Barlow SM; Knight AF Fertil Steril; 1983 Feb; 39(2):224-30. PubMed ID: 6217994 [TBL] [Abstract][Full Text] [Related]
8. Reply to comments on two articles dealing with the teratogenicity of cyproterone acetate (CA) and medroxyprogesterone acetate (MPA). Spielmann H Teratology; 1985 Oct; 32(2):319-20. PubMed ID: 2931853 [No Abstract] [Full Text] [Related]
9. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent. Jeppsson S; Gershagen S; Johansson ED; Rannevik G Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunoassay for serum medroxyprogesterone acetate in Thai women receiving injectable DMPA contraceptive. Werawatgoompa S; Pongpradit T; Leepipatpaiboon S; Sukanthanak A Contraception; 1979 Oct; 20(4):319-27. PubMed ID: 509958 [TBL] [Abstract][Full Text] [Related]
11. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624 [TBL] [Abstract][Full Text] [Related]
12. Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. II. Cyproterone acetate and medroxyprogesterone acetate treatment before implantation in vivo and in vitro. Eibs HG; Spielmann H; Jacob-Müller U; Klose J Teratology; 1982 Jun; 25(3):291-9. PubMed ID: 6214037 [TBL] [Abstract][Full Text] [Related]
13. Binding of the contraceptive steroids medroxyprogesterone acetate and ethynyloestradiol in blood of various species. Akpoviroro JO; Mangalam M; Jenkins N; Fotherby K J Steroid Biochem; 1981 May; 14(5):493-8. PubMed ID: 6457935 [TBL] [Abstract][Full Text] [Related]
14. A case for concern? Gartland A Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288 [TBL] [Abstract][Full Text] [Related]
15. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate. de Greef WJ; Dullaart J; Zeilmaker GH J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105 [TBL] [Abstract][Full Text] [Related]
16. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma. Laatikainen T; Nieminen U; Adlercreutz H Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965 [TBL] [Abstract][Full Text] [Related]
17. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea. Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303 [TBL] [Abstract][Full Text] [Related]
18. A radioimmunoassay for serum medroxyprogesterone acetate. Shrimanker K; Saxena BN; Fotherby K J Steroid Biochem; 1978 Apr; 9(4):359-63. PubMed ID: 661315 [TBL] [Abstract][Full Text] [Related]
19. Effect of injection volume on the bioavailability of sterile medroxyprogesterone acetate suspension. Wright CE; Antal EJ; Gillespie WR; Albert KS Clin Pharm; 1983; 2(5):435-8. PubMed ID: 6226473 [TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations. Stockdale AD; Chapman D; Mould GP; Rostom AY Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]